Abstract
Rho GTPase controls multiple signal-transduction pathways involving the actin cytoskeleton and the microtubule cytoskeleton in processes such as the cell cycle, morphogenesis, and cell migration. The activity of Rho GTPases, such as Rac1, Cdc42, and RhoA, is regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitor (GDI). The GEFs activate Rho GTPases through exchange of GDP for GTP. A group of the GEF family, CDM-GEF, containing the Dock180 Homology Region 2 (DHR2) domain is subdivided into four groups based on amino acid sequences. One of these subgroups, DOCK-A, includes DOCK1, DOCK2, and DOCK5, and activates Rac1 Rho GTPase. Mouse Dock5 (mDock5) is structurally similar to DOCK1 and composed of 1868 amino acids containing Src homology 3 (SH3), DHR1, DHR2, and a proline-rich (PR) motif. We generated an mDock5-specific antibody, which detected denatured and nascent forms of mDock5. We determined tissue-specific expression patterns and subcellular localization of mDock5 using this antibody. This antibody provides a way to delineate the biological functions of mDock5 in vivo.
Keywords: DOCK family, GEF, mDock5 (PPK) polyclonal antibody
Protein & Peptide Letters
Title: Characterization of an mDock5-Specific Antibody and Tissue-Specific Expression and Subcellular Localization of mDock5
Volume: 17 Issue: 4
Author(s): Eunmin Kim, Jong-Bok Yoon and SungJoo Kim Yoon
Affiliation:
Keywords: DOCK family, GEF, mDock5 (PPK) polyclonal antibody
Abstract: Rho GTPase controls multiple signal-transduction pathways involving the actin cytoskeleton and the microtubule cytoskeleton in processes such as the cell cycle, morphogenesis, and cell migration. The activity of Rho GTPases, such as Rac1, Cdc42, and RhoA, is regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitor (GDI). The GEFs activate Rho GTPases through exchange of GDP for GTP. A group of the GEF family, CDM-GEF, containing the Dock180 Homology Region 2 (DHR2) domain is subdivided into four groups based on amino acid sequences. One of these subgroups, DOCK-A, includes DOCK1, DOCK2, and DOCK5, and activates Rac1 Rho GTPase. Mouse Dock5 (mDock5) is structurally similar to DOCK1 and composed of 1868 amino acids containing Src homology 3 (SH3), DHR1, DHR2, and a proline-rich (PR) motif. We generated an mDock5-specific antibody, which detected denatured and nascent forms of mDock5. We determined tissue-specific expression patterns and subcellular localization of mDock5 using this antibody. This antibody provides a way to delineate the biological functions of mDock5 in vivo.
Export Options
About this article
Cite this article as:
Kim Eunmin, Yoon Jong-Bok and Yoon Kim SungJoo, Characterization of an mDock5-Specific Antibody and Tissue-Specific Expression and Subcellular Localization of mDock5, Protein & Peptide Letters 2010; 17 (4) . https://dx.doi.org/10.2174/092986610790963681
DOI https://dx.doi.org/10.2174/092986610790963681 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Current Gene Therapy Strategies for Colorectal Cancer
Current Genomics Synthetic Approaches to Functionalized Lipids for Protein Monolayer Crystallizations
Current Organic Chemistry Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Research Advances in Neuroblastoma Immunotherapy
Current Pediatric Reviews Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Enhancement Antimicrobial Activity of Clarithromycin by Amine Functionalized Mesoporous Silica Nanoparticles as Drug Delivery System
Letters in Drug Design & Discovery Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Controlled Gene Delivery Can Enhance Therapeutic Outcome for Cancer Immune Therapy for Melanoma
Current Gene Therapy Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies